Connect with us

Business

BioNTech CEO says the vaccine will likely work on new U.K. virus variant

Published

on

BioNTech CEO says the vaccine will likely work on new U.K. virus variant


Pfizer Inc. partner BioNTech SE is pursuing all its options to make more Covid-19 vaccine doses than the 1.3 billion the companies have promised to produce next year, according to the German firm’s chief executive officer.

The companies will probably know by January or February whether and how many additional doses can be produced, Ugur Sahin said late Monday in an interview. “I am confident that we will be able to increase our network capacity, but we don’t have numbers yet.”

Sahin also said the vaccine will probably work against the new SARS-CoV-2 strain that has emerged in the U.K. Lab tests of the vaccine’s performance have already been done against 20 mutant versions; the same tests will now be run against the new U.K. version, and should take about two weeks, he said.

Efficacy results of more than 90% and approvals around the world have set off a race between countries for additional supplies of the precious shots, with the U.S. seeking to exercise an option for a hundred million. Most of the doses anticipated for next year — enough to immunize 650 million people — have already been spoken for.

More than 2 million people in six countries have already gotten their first shot of the standard two-dose regimen, according to data collected by Bloomberg.

BioNTech is seeking more of the raw materials it needs for its mRNA vaccine, more clean rooms and more cooperation partners, Sahin said. The company also needs additional space to formulate the shots, put them into containers and prepare them for shipping, he said. Pfizer is producing vaccine at three sites in the U.S. and one in Europe, while BioNTech has two manufacturing sites in Germany.

The vaccine’s EU approval and an inoculation campaign set to start there on Dec. 27 promise to further draw on stocks. By the end of 2020, BioNTech expects to ship 12.5 million doses to the EU and 20 million to the U.S., the company said in a press conference on Tuesday. The partners have already begun shipping shots to the U.K., where Health Secretary Matt Hancock on Monday tweeted that some 500,000 people had gotten their first dose.

New Strain Tests

If the vaccine turns out to be ineffective against the mutant strain circulating in the U.K., BioNTech could, in theory, produce a new Covid vaccine to fight the variant within six weeks, Sahin said at the Tuesday briefing. How fast the new inoculation could get to patients would depend on the speed of regulatory review.

But so far, Sahin sees no reason to doubt that the existing shot will be effective. Most vaccines target the spike protein, which allows the virus to enter cells.

“This virus has multiple mutations, but as far as we know, 99% of the spike protein is not mutated,” he said late Monday. “Let’s do the experiment and get the result. That’s always the best answer, but I would emphasize just to stay calm.”

–With assistance from Riley Griffin and Iain Rogers.

More health care and Big Pharma coverage from Fortune:

  • The COVID-19 vaccine rollout is dangerously flawed. Science and data could fix it
  • How hackers could undermine a successful vaccine rollout
  • “There simply isn’t the trust”: The fight to overcome vaccine skepticism in the Black community
  • You can now get personalized updates on the COVID vaccine from Zocdoc
  • Here’s how much Europe will pay for each COVID-19 vaccine

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

The maker behind the world’s first-ever PMS gummy vitamin

Published

on

The maker behind the world’s first-ever PMS gummy vitamin


© 2020 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell My Personal Information | Ad Choices 
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html.
S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Continue Reading

Business

U.S. and EU agree to suspend tariffs amid hopes of a ‘fresh start’ from the bruising Trump trade wars

Published

on

U.S. and EU agree to suspend tariffs amid hopes of a 'fresh start' from the bruising Trump trade wars



The truce means a pause on tariffs levied against aircraft, wine, food and other products, many of which stem from the Trump era trade war.
Read More

Continue Reading

Business

Brexit has saddled its champions with an impossible dilemma

Published

on

Brexit has saddled its champions with an impossible dilemma



The Northern Ireland problem keeps getting more problematic. Read More

Continue Reading

Copyright © 2020 Diliput News.